Scandinavian ChemoTech

The financing forms part of ChemoTech's long-term financial strategy and will support the Company's commercial expansion within Animal Care in North America and Europe. By strengthening sales and marketing capacity, the loan is expected to contribute to increased revenues and accelerate the Company's path toward profitability. It also enhances ChemoTech's financial flexibility by enabling other funds to be reallocated toward the continued development of the TSE platform.

The loan is being provided on highly competitive terms, with an interest rate considerably lower than the Company's existing loans. The loan term is 36 months and is interest-only for the first eight months. It will be disbursed in two installments of SEK 3 million each.

"We are entering a very exciting phase in ChemoTech's development, where both our technology platform and business model are demonstrating strong progress and validation. This financing has become accessible to us as a result of our strong revenue growth over the past two years and represents an important step, giving us additional resources to accelerate key initiatives, strengthen our organization, and support the recruitment of critical talent as we scale our operations.

The loan will enable us to expand our efforts to grow the installed base of TSE systems and increase the usability of TSE therapy among veterinarians. By duplicating best practices and helping clinics increase treatment frequency, we aim to support improved clinical outcomes while also contributing to stronger profitability for our clients," says Mohan Frick, CEO of Scandinavian ChemoTech.